Evidence map›Paper›PMID 36971691›Full record

ArticleJournal of surgical oncology2023

Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.

Lodewijka H J Holtkamp, Serigne N Lo, John F Thompson, Andrew J Spillane, Jonathan R Stretch, Robyn P M Saw, Kerwin F Shannon, Omgo E Nieweg, Angela M Hong

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Radiation and Melanoma: Where Are We Now?Current oncology reports · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Lodewijka H J HoltkampMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-7720-0639
Serigne N LoMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-5092-5544
John F ThompsonMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
Andrew J SpillaneMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8354-434X
Jonathan R StretchMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
Robyn P M SawMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
Kerwin F ShannonMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8538-3132
Omgo E NiewegMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
Angela M HongMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
The University of Sydney · AU

Funding

Australian National Health and Medical Research Council APP1093017Groningen Melanoma and Sarcoma FoundationMelanoma Institute AustraliaVreedefonds
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAdjuvant radiotherapy (RT) can be given to melanoma patients following salvage surgery for node field recurrence after a previous regional node dissection, but the value of this treatment strategy is poorly documented. This study evaluated long-term node field control and survival of patients treated in this way in an era before effective adjuvant systemic therapy became available.

methodsData for 76 patients treated between 1990 and 2011 were extracted from an institutional database. Baseline patient characteristics, treatment details and oncological outcomes were analysed.

resultsAdjuvant RT with conventional fractionation (median dose 48 Gy in 20 fractions) was given to 43 patients (57%) and hypofractionated RT (median dose 33 Gy in 6 fractions) to 33 patients (43%). The 5-year node field control rate was 70%, 5-year recurrence-free survival 17%, 5-year melanoma-specific survival 26% and 5-year overall survival 25%.

conclusionsSalvage surgery with adjuvant RT achieved node field control in 70% of melanoma patients with node field recurrence following a prior node dissection. However, disease progression at distant sites was common and survival outcomes were poor. Prospective data will be required to assess outcomes for contemporary combinations of surgery, adjuvant RT and systemic therapy.

Indexed as

MelanomaSkin NeoplasmsHumansLymphatic MetastasisLymph Node ExcisionNeoplasm Recurrence, LocalProspective StudiesRadiotherapy, AdjuvantRetrospective Studiesadjuvant radiotherapylymph node metastasismelanoma

Identifiers

PMID36971691
PMCPMC10952220
OpenAlexW4361002208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.